Weight Gai

Weight Gain in Young, Middle-Aged Adults Linked to Poor Heart Health in Older Age

People who gain excess weight at age ≥20 years are more likely to have adverse cardiac structure and function later in life, according to a study published in the European Heart Journal. “We know that being overweight is associated with poorer heart health, but we know little about the long-term relationship between being overweight over the adult life course and subsequent heart health,” said Alun Hughes, MD, University College London, London, United Kingdom. “We wanted to look at whether being overweight at earlier stages of adult life showed lasting associations with poorer heart health ...

Antihypertensive drug treatment and the risk for intra-hemodialysis hypotension

BACKGROUND Antihypertensive medications are often prescribed to manage hypertension in hemodialysis (HD) patients, and intradialytic hypotension (IDH) is a common complication in these patients. We investigated the risk of IDH in incident HD patie

Study Confirms Safety of Pulsed Field Ablation for Atrial Fibrillation

A post-approval study, published in Nature Medicine, has shown that pulsed field ablation (PFA) is a safe modality for treating patients with atrial fibrillation (AF). Radiofrequency ablation and cryoablation -- the 2 most common forms of ablation...


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
How to tre
14:51

How to treat atherosclerosis? - Highlights of the EAS 2024 (Part I)

Presenter: Philippe Moulin
Cardiology : Atherosclerosis
EAS 2024
How to tre
14:16

How to treat atherosclerosis? - Highlights of the EAS 2024 (Part II)

Presenter: Philippe Moulin
Cardiology : Atherosclerosis
EAS 2024
75th Anniv
4:59

75th Anniversary of Glucocorticoids - what have we learnt?

Presenter: Sytske Anne Bergstra
Internal Medicine
EULAR 2024
Update of
4:48

Update of EULAR recommendations for the treatment of Systemic Sclerosis

Presenter: Francesco Del Galdo
Internal Medicine
EULAR 2024
Promising
5:13

Promising directions in the treatment of Psoriatic Arthritis

Presenter: Rik Lories
Internal Medicine
EULAR 2024
Interstiti
6:06

Interstitial Lung Disease: from diagnosis to management

Presenter: Anna-Maria Hoffmann-Vold
Internal Medicine
EULAR 2024
What is Ne
7:12

What is New : Osteoporosis in Rheumatology

Presenter: Willem Lems
Internal Medicine
EULAR 2024
Effectiven
5:48

Effectiveness of Canakinumab for first line steroid free treatment in systemic juvenile idiopathic arthritis - report from EULAR2024

Presenter: Gerd Horneff
Internal Medicine
EULAR 2024
Early and
9:21

Early and maintained comparative effectiveness of 5 different classes of advanced therapies in a large multinational cohort of real-world PsA patients

Internal Medicine
EULAR 2024
Fatigue, P
11:11

Fatigue, Pain and Opioids in Rheumatological Diseases

Presenter: Rene Westhovens
Internal Medicine
EULAR 2024
Cardiovasc
3:54

Cardiovascular Comorbidities of Rheumatic and Musculoskeletal Diseases

Presenter: Anja Strangfeld
Internal Medicine
EULAR 2024
Update on
5:00

Update on EULAR/ACR Project: Risk Stratification in patients with arthralgia suspicious for progression to RA

Presenter: Annette H. M. van der Helm van Mil
Internal Medicine
EULAR 2024
Difficult
9:43

Difficult Questions in Osteoporosis

Presenter: Roland Chapurlat
Internal Medicine
EULAR 2024
Secukinuma
6:32

Secukinumab versus standard-of-care in axial spondyloarthritis

Presenter: Denis Poddubnyy
Internal Medicine
EULAR 2024
Lupus: wha
10:48

Lupus: what's on the horizon?

Presenter: David Isenberg
Internal Medicine
EULAR 2024
Overview o
2:48

Overview of the 2024 EAS Congress

Presenter: Kausik K Ray
Cardiology : Atherosclerosis
EAS 2024
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
The import
11:22

The importance of the anterior interface in eye surgery

Presenter: Marie-José Tassignon
Internal Medicine
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Oncology
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Oncology
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology